Literature DB >> 15940635

Use of adenovirus-delivered siRNA to target oncoprotein p28GANK in hepatocellular carcinoma.

Honghai Li1, Xiaoyong Fu, Yao Chen, Yi Hong, Yexiong Tan, Huifang Cao, Mengchao Wu, Hongyang Wang.   

Abstract

BACKGROUND & AIMS: RNA interference (RNAi) is a powerful tool to silence gene expression. The adenoviral vector expressing small interfering RNA (siRNA) is highly effective in mammalian cells. However, its potential use as a therapeutic tool to target an oncogene specifically remains to be seen. We applied the adenovirus-delivered siRNA (AdSiRNA) to inhibit a hepatocellular carcinoma (HCC) oncogene, p28GANK, in HCC cell lines and investigated its antitumor effects.
METHODS: The T7-RNA polymerase system was used to screen the specific target site. Double-strand oligonucleotide for transcription of short hairpin RNA was constructed into the adenoviral vector. Four HCC cell lines were infected with the RNAi-containing adenovirus. The RNAi effects on HCC were studied in cultured cells as well as in animal models.
RESULTS: p28GANK expression was suppressed by up to 80% in HCC cells. Depletion of p28GANK inhibited HCC cell growth and tumorigenesis, enhanced dephosphorylation of RB1, and decreased transcription activity of E2F-1 in HuH-7 cells. Furthermore, depletion of p28GANK induced caspase-8- and caspase-9-mediated apoptosis of HCC cells. Finally, targeting p28GANK by adenovirus injection inhibited the growth of established tumors in nude mice.
CONCLUSIONS: This study shows that the T7-system screening-based AdSiRNA can be used successfully to silence an oncogene. We proved the therapeutic potential of AdSiRNA on the treatment of HCC by targeting p28GANK. Our results indicate that p28GANK may serve as a novel therapeutic target for treating HCC.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15940635     DOI: 10.1053/j.gastro.2005.03.001

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  22 in total

1.  RNA interference targeting CITRON can significantly inhibit the proliferation of hepatocellular carcinoma cells.

Authors:  Yinghui Fu; Jian Huang; Ke-Sheng Wang; Xin Zhang; Ze-Guang Han
Journal:  Mol Biol Rep       Date:  2010-04-06       Impact factor: 2.316

2.  Modulation of the unfolded protein response is the core of microRNA-122-involved sensitivity to chemotherapy in hepatocellular carcinoma.

Authors:  Fu Yang; Ling Zhang; Fang Wang; Yue Wang; Xi-song Huo; Yi-xuan Yin; Yu-qi Wang; Lin Zhang; Shu-han Sun
Journal:  Neoplasia       Date:  2011-07       Impact factor: 5.715

3.  Progression of cancer from indolent to aggressive despite antigen retention and increased expression of interferon-gamma inducible genes.

Authors:  Terry H Wu; Karin Schreiber; Ainhoa Arina; Nikolai N Khodarev; Elena V Efimova; Donald A Rowley; Ralph R Weichselbaum; Hans Schreiber
Journal:  Cancer Immun       Date:  2011-06-30

Review 4.  Gene therapy of liver cancer.

Authors:  Ruben Hernandez-Alcoceba; Bruno Sangro; Jesus Prieto
Journal:  World J Gastroenterol       Date:  2006-10-14       Impact factor: 5.742

Review 5.  Intracellular signaling and hepatocellular carcinoma.

Authors:  Polina Iakova; Lubov Timchenko; Nikolai A Timchenko
Journal:  Semin Cancer Biol       Date:  2010-09-17       Impact factor: 15.707

Review 6.  Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma.

Authors:  Jaleh Varshosaz; Maryam Farzan
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

7.  Expression of RNA interference triggers from an oncolytic herpes simplex virus results in specific silencing in tumour cells in vitro and tumours in vivo.

Authors:  Anna-Maria Anesti; Guy R Simpson; Toby Price; Hardev S Pandha; Robert S Coffin
Journal:  BMC Cancer       Date:  2010-09-13       Impact factor: 4.430

8.  Silencing of FOXM1 transcription factor expression by adenovirus-mediated RNA interference inhibits human hepatocellular carcinoma growth.

Authors:  T Chen; J Xiong; C Yang; L Shan; G Tan; L Yu; Y Tan
Journal:  Cancer Gene Ther       Date:  2014-02-28       Impact factor: 5.987

Review 9.  Harnessing the RNA interference pathway to advance treatment and prevention of hepatocellular carcinoma.

Authors:  Patrick Arbuthnot; Liam-Jed Thompson
Journal:  World J Gastroenterol       Date:  2008-03-21       Impact factor: 5.742

10.  Analysis of the mechanisms mediating tumor-specific changes in gene expression in human liver tumors.

Authors:  Luis G Acevedo; Mark Bieda; Roland Green; Peggy J Farnham
Journal:  Cancer Res       Date:  2008-04-15       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.